The aim is to assess the clinical features and treatment outcomes of dermatomyositis induced by anti-PD-1/PD-L1 therapy.
Monitoring cutaneous and muscular symptoms in patients undergoing anti-PD-1/PD-L1 therapy.
Implementing interventions based on the severity of symptoms in diagnosed dermatomyositis cases.
Recommends early detection of dermatomyositis during treatment.
Highlights the need for timely interventions according to symptom severity.
Abstract
During anti-PD-1/PD-L1 therapy, closely monitor patients' cutaneous and muscular symptoms to detect DM early. For diagnosed DM patients, implement timely interventions according to symptom severity.